The patent for FCL AHA Lightening Gel HQ reinforces Fixderma’s science-first approach and positions it as the only Indian skincare company with two patented dermatological formulations
Fixderma Cosmetic Laboratories (FCL), a science-driven, dermatologist-prescribed skincare brand, has secured a patent for its FCL AHA Lightening Gel HQ, marking a significant milestone in its research-led growth journey. With this development, Fixderma becomes the only Indian skincare company to hold two patents for dermatological formulations, underlining its long-term commitment to clinical innovation over cosmetic trends.
The newly patented product forms part of Fixderma’s prescription-based (RX) portfolio and has been prescribed by more than 15,000 doctors since the brand’s inception. It is widely used in the management of pigmentation, uneven skin tone and dullness, and is recommended as part of dermatologist-supervised skincare regimens.
This patent follows the earlier success of Nigrifix Cream, Fixderma’s first patented formulation developed for targeted hyperpigmentation concerns. Together, the two patents reinforce the company’s positioning as a dermatology-led brand rooted in advanced research, clinical validation and consistent outcomes.
Developed through extensive dermatological research, the FCL AHA Lightening Gel HQ features a patent-protected combination of Alpha Hydroxy Acids (AHAs) designed to deliver controlled and targeted exfoliation while maintaining skin barrier integrity. Its lightweight gel formulation enhances penetration and tolerability, making it suitable for long-term use under professional guidance.
Commenting on the achievement, Anurag Mehrotra, Chairman, Fixderma, said the second patent reflects years of rigorous research and uncompromising quality standards. He added that the complex nature of the patenting process makes the recognition particularly meaningful and reinforces Fixderma’s standing among a select group of Indian skincare innovators.
Mehrotra also highlighted the brand’s growing global footprint, noting that Fixderma currently exports to over 40 countries, including Nepal, Cambodia, Malaysia and Ethiopia. The company recently received its first order from South Africa, signalling rising international confidence in Indian dermatological innovation.
Shaily Mehrotra, CEO, Fixderma, said the patent represents a broader milestone for India’s dermatology-focused skincare segment. She noted that the FCL AHA Lightening Gel HQ has earned long-standing trust among dermatologists and that the patent further validates Fixderma’s philosophy of building effective, safe and clinically relevant formulations through science-led innovation.
Welcoming the development, Dr Nishita Ranka, Dermatologist, who has been prescribing FCL products for over five years, said the patent is a testament to Fixderma’s scientific rigour and consistency. She added that it is encouraging to see Indian brands setting high benchmarks in clinical skincare.
The FCL AHA Lightening Gel HQ is available through dermatology clinics and authorised skincare platforms across India.
